The DOI matches its Crossref record.
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo
Open accessAbstract
Dysregulation of the ubiquitin‐proteasome pathway plays an essential role in tumor growth and development. Shikonin, a natural naphthoquinone isolated from the traditional Chinese medicine Zi Cao (gromwell), has been reported to possess tumor cell‐killing activity, and results from a clinical study using a shikonin‐containing mixture demonstrated its safety and efficacy for the treatment of late‐stage lung cancer. In this study, we reported that shikonin is an inhibitor of tumor proteasome activity in vitro and in vivo. Our computational modeling predicts that the carbonyl carbons C 1 and C 4 of shikonin potentially interact with the catalytic site of β5 chymotryptic subunit of the proteasome. Indeed, shikonin potently inhibits the chymotrypsin‐like activity of purified 20S proteasome (IC 50 12.5 μmol/L) and tumor cellular 26S proteasome (IC 50 between 2–16 μmol/L). Inhibition of the proteasome by shikonin in murine hepatoma H22, leukemia P388 and human prostate cancer PC‐3 cultures resulted in accumulation of ubiquitinated proteins and several proteasome target proapoptotic proteins (IκB‐α, Bax and p27), followed by induction of cell death. Shikonin treatment resulted in tumor growth inhibition in both H22 allografts and PC‐3 xenografts, associated with suppression of the proteasomal activity and induction of cell death in vivo. Finally, shikonin treatment significantly prolonged the survival period of mice bearing P388 leukemia. Our results indicate that the tumor proteasome is one of the cellular targets of shikonin and inhibition of the proteasome activity by shikonin contributes to its antitumor property. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
Chen, J., Xie, J., Jiang, Z., Wang, B., Wang, Y., & Hu, X. (2011) · Oncogene · doi:10.1038/onc.2011.137 · Cited by 512
Anti-cancer natural products isolated from chinese medicinal herbs
Tan, W., Lu, J., Huang, M., Li, Y., Chen, M., Wu, G., Gong, J., Zhong, Z., Xu, Z., Dang, Y., et al. (2011) · Chinese Medicine · doi:10.1186/1749-8546-6-27 · Cited by 396
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
Inoue, H., & Tani, K. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.84 · Cited by 347
Pharmacological Properties of Shikonin – A Review of Literature since 2002
Andújar, I., Ríos, J., Giner, R., & Recio, M. (2013) · Planta Medica · doi:10.1055/s-0033-1350934 · Cited by 282
Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis
Ding, H., Jiang, L., Xu, J., Bai, F., Zhou, Y., Yuan, Q., Luo, J., Zen, K., & Yang, J. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00036.2017 · Cited by 250
Metadata
- Authors
- Yang, H., Zhou, P., Huang, H., Chen, D., Ma, N., Cui, Q. C., Shen, S., Dong, W., Zhang, X., Lian, W., Wang, X., Dou, Q. P., & Liu, J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-03-16
- Volume
- 124
- Issue
- 10
- Pages
- 2450-2459
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2004782513
- Cited by
- 158
- References
- 0
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. https://app.cochat.ai/papers/10.1002/ijc.24195
- The paper
- Yang, H., Zhou, P., Huang, H., Chen, D., Ma, N., Cui, Q. C., Shen, S., Dong, W., Zhang, X., Lian, W., Wang, X., Dou, Q. P., & Liu, J. (2009). Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. International Journal of Cancer. https://doi.org/10.1002/ijc.24195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.